PRP vs BMAC in Knee Osteoarthritis: What Does the Latest Evidence Really Show?
Regenerative medicine has transformed the non-surgical management of knee osteoarthritis (KOA). Among these biologic options, Platelet-Rich Plasma (PRP) and Bone Marrow Aspirate Concentrate (BMAC) have emerged as two commonly discussed therapy choices. Both are autologous, minimally invasive, and intended to reduce inflammation while supporting joint repair.
However, patients and clinicians frequently ask:
“Is BMAC better than PRP?”
A new systematic review and meta-analysis published by our team at Daradia: The Pain Clinic provides one of the most updated answers to this question.
Below, we break down the findings in clear terms.
PRP vs BMAC Journal Club Meeting
What Were the Findings of the Meta-Analysis?
A total of three clinical studies (two randomized controlled trials and one comparative retrospective study) were included, evaluating 186 patients treated with BMAC and 88 treated with PRP efficacy_of_bone_marrow_aspirat….
1. Pain Relief
Across all time points (1–12 months), BMAC and PRP produced similar reductions in pain scores.
There was no significant advantage of BMAC over PRP in relieving pain.
2. Functional Improvement
Some functional scores—such as IKDC at certain time points—showed small improvements in the BMAC group.
However, these were not consistently replicated, and results showed significant heterogeneity, meaning the evidence is not strong or uniform across studies.
3. WOMAC & KOOS Scores
While isolated intervals showed slightly better improvements with BMAC, the overall pooled data confirmed no major or clinically meaningful difference between the two treatments.
4. Safety
Both PRP and BMAC were safe, well-tolerated, and associated only with transient post-procedure discomfort.
So, Is BMAC Superior to PRP?
Based on currently available clinical evidence, the answer is NO.
The latest systematic review and meta-analysis concludes:
Both PRP and BMAC provide comparable improvement in pain and function in knee osteoarthritis, with no consistent evidence showing BMAC to be superior.
efficacy_of_bone_marrow_aspirat…
Some studies showed small functional advantages with BMAC at select follow-up points, but these findings were not robust enough to establish clear superiority.
Why This Matters for Patients
- PRP is less invasive (no bone marrow aspiration required).
- PRP is significantly more cost-effective.
- Evidence does not justify choosing BMAC solely for better outcomes, as results remain similar.
- Patient preference, cost, procedural invasiveness, and availability should guide treatment decisions.
Important: This Recommendation May Change with Future Research
We emphasize that:
As more high-quality randomized controlled trials become available, future recommendations may change.
Today’s evidence is limited by:
- Small number of RCTs
- Heterogeneity in preparation techniques
- Variable OA severity across studies
- Lack of long-term (>24 months) data
Thus, while current evidence shows no advantage of BMAC over PRP, ongoing trials may provide more clarity.
Daradia remains committed to updating our clinical recommendations as new evidence emerges.
Daradia’s Clinical Perspective
At Daradia, we offer both PRP and BMAC for knee osteoarthritis.
Given the current evidence:
- PRP is often recommended as the first-line orthobiologic option due to similar outcomes and lower invasiveness.
- BMAC may be considered in select cases where patients prefer it or when PRP has been tried but failed to provide satisfactory benefit.
- All decisions are individualized based on clinical assessment, imaging, patient expectations, and budget.
Final Takeaway
PRP and BMAC are both effective regenerative therapies for knee osteoarthritis.
But with the research we have today, BMAC has not proven to be superior to PRP.
We will continue to analyze ongoing studies and update our recommendations as stronger evidence emerges.
